# Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

> **NCT05096208** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1028 (actual)

## Conditions studied

- RSV

## Interventions

- **BIOLOGICAL:** RSVpreF (Group 1)
- **BIOLOGICAL:** RSVpreF (Group 2)
- **BIOLOGICAL:** RSVpreF (Group 3)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05096208
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-21
- **Primary completion:** 2022-04-04
- **Final completion:** 2022-04-04
- **Target enrollment:** 1028 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096208, "Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05096208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*